Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 7/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7621104 | 0.89 | OPRM1 (0.48) | OPRM1SIGMAR1KDM4EALDH1A1CYP2D6 | |
| SCHEMBL7625846 | 0.83 | OPRM1 (0.46) | OPRM1SIGMAR1KDM4EALDH1A1CYP2D6 | |
| SCHEMBL6603001 | 0.79 | OPRM1 (0.47) | OPRM1SIGMAR1ALDH1A1CYP2D6LMNA | |
| SCHEMBL7618708 | 0.76 | ALDH1A1 (0.50) | OPRM1SIGMAR1ALDH1A1CYP2D6LMNA | |
| SCHEMBL6603960 | 0.76 | KDM4E (0.50) | OPRM1SIGMAR1KDM4EKCNH2 | |
| SCHEMBL7618700 | 0.75 | NPFFR1 (0.52) | SIGMAR1ALDH1A1CYP2D6KCNH2 | |
| SCHEMBL7629192 | 0.74 | SIGMAR1 (0.56) | SIGMAR1ALDH1A1CYP2D6LMNAKMT2A | |
| SCHEMBL7631442 | 0.73 | NPFFR1 (0.52) | SIGMAR1KDM4EALDH1A1CYP2D6KCNH2 | |
| SCHEMBL7623544 | 0.72 | OPRM1 (0.49) | OPRM1SIGMAR1KDM4ECYP2D6KMT2A | |
| SCHEMBL7625460 | 0.71 | SIGMAR1 (0.49) | SIGMAR1KDM4EALDH1A1CYP2D6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6444677-B2 | TREATMENT OF INFLAMMATION, CARDIOVASCULAR DISEASE, PAIN, ETC. | PFIZER INC. | 2002-09-03 | — | — | US | disclosed |
| US-20010046993-A1 | 5-memberd heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists | IKEDA TAKAFUMI (JP) | 2001-11-29 | — | — | US | disclosed |
| EP-1106614-A1 | 5-Membered heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER INC. (US) | 2001-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010046993-A1 | 5-memberd heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists | BDKRB1, BDKRB2, CNR2 | OPRM1 42/4885SIGMAR1 127/4885KDM4E 2675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.